Despite positive clinical evidence, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing considerable opposition from managed care entities. Such insurers are typically building limitations to coverage, like significant cost criteria and prior authorization that restrict consumer access. Market